[Preliminary mechanism of paclitaxel enhanced radiation sensitivity for nasopharyngeal carcinoma cells]

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2014 Aug;28(15):1129-32, 1136.
[Article in Chinese]

Abstract

Objective: To study the radiation-sensitizing function and preliminary mechanism of paclitaxel in radiation-resistant nasopharyngeal carcinoma cells.

Method: X-ray dose fractionated irradiation technology to build radiation-resistant subline of nasopharyngeal carcinoma; CNE-2S1 was treated with paclitaxel alone or combined with radiation therapy, while control group treated with radiation therapy; cell colony formation assay was used to observe sensitizing effect of paclitaxel on radiotherapy; flow cytometry analysis was used to analyze cell cycle distribution and apoptosis ratio of different treatment groups; immunoblotting was used to analyze SHP-1 expression levels of different treatment groups.

Result: Nasopharyngeal carcinoma cells resistant to radiation was successfully established; cell colony formation assay showed that paclitaxel has obvious sensitizing effect on radiotherapy; FACS results showed that: CNE-2S1 treated by paclitaxel were arrested in G2M phase; paclitaxel and radiotherapy treatments significantly improved the CNE-2S1 apoptosis ratio; Western blot results showed that paclitaxel and combined radiotherapy can reduce the CNE-2S1 cells SHP-1 expression levels.

Conclusion: Paclitaxel enhanced radiation therapy for nasopharyngeal carcinoma cells resistant to radiation, and SHP-1 may be involved in this progress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Carcinoma
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Humans
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / pathology*
  • Paclitaxel / pharmacology*
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6 / metabolism
  • Radiation Tolerance / drug effects*

Substances

  • PTPN6 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • Paclitaxel